Effect of ursodeoxycholic acid administration on nucleation time in human gallbladder bile.
The object of this study was to determine the effects of ursodeoxycholic acid administration on metastability in human gallbladder bile, as reflected by nucleation time. Bile samples from 10 patients with cholesterol gallstones who underwent preoperative ursodeoxycholic acid treatment exhibited a significantly longer median nucleation time (16 days) than those from 11 patients with cholesterol gallstones who received no preoperative treatment (4 days) (p less than 0.01). On the other hand, the median nucleation times of bile samples from 15 patients with noncholesterol gallstones and 24 patients without gallstones were 15 and 14 days, respectively. In addition, 3 mo of treatment with ursodeoxycholic acid significantly elevated the serum concentration of the antinucleating factor apolipoprotein A-I, from 133.3 +/- 12.3 to 148.6 +/- 13.2 mg/dl (p less than 0.05). These findings suggest that ursodeoxycholic acid retards cholesterol crystal nucleation, thereby inhibiting cholesterol gallstone formation. It is also possible that serum apolipoprotein A-I plays a role in this process.
Tazuma
S
S
First Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
Sasaki
H
H
Mizuno
S
S
Sagawa
H
H
Hashiba
S
S
Horiuchi
I
I
Kajiyama
G
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000097:blood; D001646:Bile / Q000502:physiology*; D002769:Cholelithiasis / Q000503:physiopathology*; D002784:Cholesterol / Q000378:metabolism; D003840:Deoxycholic Acid / Q000031:analogs & derivatives*; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D008875:Middle Aged; D011300:Preoperative Care; D014580:Ursodeoxycholic Acid / Q000494:pharmacology*
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D008075:Lipoproteins, HDL; D003840:Deoxycholic Acid; D014580:Ursodeoxycholic Acid; D002784:Cholesterol